tbuckley/cabot-search huggingface dataset:
Early complications of organ preservation treatment in head and neck cancer, UAMS experience
Authors: A. A. Khalid, J. E. Morgan, S. Horace, E. Y. Hanna, R. Breau, M. J. Kyasa, A.-M. Maddox
Journal: Journal of Clinical Oncology (2004)

5607 Background Patients undergoing organ preservation treatment (chemotherapy/radiation therapy) for squamous cell cancer of the head and neck (SCCHN) develop many early complications. Early recognition of these complications may reduce morbidity and hospitalization. Methods Retrospective analysis of patients undergoing organ preservation treatment for SCCHN at UAMS from 10–92 through 8–02. Incidence of mucositis, neutropenia, wt loss, renal impairment, gastrostomy tube placement (PEG) and hospitalization due to complications was gathered from chart review, electronic medical records and the database maintained at division of head and neck surgery at UAMS. Results 147 patients were evaluated. 109 (74.15%) were male and 38 (25.85%) were female. Most common site was base of tongue (20.41%) followed by larynx (17.69%).Median age at diagnosis was 58 yrs. 56.46% had stage IV disease, 34.01% had stage III. Incidence of grade II neutropenia was 21.98%, grade III 23.08% grade IV 13.19%. Grade II mucositis was 11.61%, grade III 18.75%, grade IV 19.64%.Incidence of grade I wt loss was 15.3%, grade II 44% and grade III 6.4%. Grade I renal insufficiency was 21%, grade II 3.7% and grade III in 3.7%.PEG was placed prior to treatment in 78(60%) of patients, 18 (13.85%) during treatment, 28 (21.54%) did not receive PEG. Hospitalization due to the complications was required in 55.48% Mean length of hospital stay (LOS) was 9.6 days (range 1–72). There was no statistically significant difference in the median LOS of patients who received PEG prior to treatment and those who received PEG during treatment. Conclusions Organ preservation treatment of SCCHN is associated with tolerable early complications including mucositis, neutropenia, renal impairement and wt loss often requiring hospitalization for management. No significant financial relationships to disclose.
Predicting residual kidney function in hemodialysis patients using serum β-trace protein and β2-microglobulin
Authors: Jonathan Wong, Sivakumar Sridharan, Jocelyn Berdeprado, Enric Vilar, Adie Viljoen, David Wellsted, Ken Farrington
Journal: Kidney International (2016)

Residual kidney function (RKF) contributes significant solute clearance in hemodialysis patients. Kidney Diseases Outcomes Quality Initiative (KDOQI) guidelines suggest that hemodialysis dose can be safely reduced in those with residual urea clearance (KRU) of 2 ml/min/1.73 m(2) or more. However, serial measurement of RKF is cumbersome and requires regular interdialytic urine collections. Simpler methods for assessing RKF are needed. β-trace protein (βTP) and β2-microglobulin (β2M) have been proposed as alternative markers of RKF. We derived predictive equations to estimate glomerular filtration rate (GFR) and KRU based on serum βTP and β2M from 191 hemodialysis patients based on standard measurements of KRU and GFR (mean of urea and creatinine clearances) using interdialytic urine collections. These modeled equations were tested in a separate validation cohort of 40 patients. A prediction equation for GFR that includes both βTP and β2M provided a better estimate than either alone and contained the terms 1/βTP, 1/β2M, 1/serum creatinine, and a factor for gender. The equation for KRU contained the terms 1/βTP, 1/β2M, and a factor for ethnicity. Mean bias between predicted and measured GFR was 0.63 ml/min and 0.50 ml/min for KRU. There was substantial agreement between predicted and measured KRU at a cut-off level of 2 ml/min/1.73 m(2). Thus, equations involving βTP and β2M provide reasonable estimates of RKF and could potentially be used to identify those with KRU of 2 ml/min/1.73 m(2) or more to follow the KDOQI incremental hemodialysis algorithm.
Friable Nodules on the Elbow of a Transplant Patient
Authors: Ben J. Friedman, Dhwani Mehta, Marsha L. Chaffins
Journal: JAMA Dermatology (2016)

An immunosuppressed man in his 60s was admitted for hypertensive urgency, and a dermatologist was consulted during his admission to evaluate a friable, growing lesion on his right elbow that had appeared 2 months prior. What is your diagnosis?
Abstract 12470: Computational Evaluation of Myocardial Performance from Four-Dimensional Images
Authors: Shengyong Chen, Zhongzhao Teng, Qiu Guan, Jianwei Zhang
Journal: Circulation (2012)

Introduction: In four-dimensional cardiac images, myocardial motion and deformation at every local point can be tracked by combination of model-based shape analysis and finite element method. With ...
Clinical significance of isolated tumor cell detection in peripheral blood in breast cancer patients three years after diagnosis. Comparison between analysis of peripheral blood and bone marrow
Authors: B. Naume, G. Wiedswang, E. Borgen, C. Schirmer, G. Kvalheim, R. Kaaresen, J. M. Nesland
Journal: Journal of Clinical Oncology (2004)

9554 Background: The detection of isolated tumor cells (ITC) in bone marrow (BM) in breast cancer by immunocytochemical (ICC) methods predicts future systemic relapse and death. Peripheral blood (PB) is easier to obtain than BM, but the clinical significance of ITC detection in PB is still not settled. The analysis of the same number of mononuclear cells (MNC) in PB as for BM results in a markedly lower number of ITC-positive samples. Analysing larger numbers of PBMNC can possibly improve the clinical significance of ITC-detection. This principle was tested and compared to the standard BM analysis by ICC. Methods: Peripheral blood and BM were collected from early breast cancer patients 40 months (median) after operation. Peripheral blood MNC were analysed by a negative immunomagnetic technique (10x106 cells/test) followed by ICC. Bone marrow aspirates from the same patients were analysed by a standard direct ICC method (2x106 cells/test). Results: Of the 96 node-positive patients analysed so far, 18 had ITC in PB by negative IMS (19%). In BM, 21% of the patients were positive (20/96). Seven patients were positive both in PB and BM (7%). After median 63 months FU from diagnosis, 16 systemic relapses and 10 breast cancer deaths have occurred. Systemic relapse and breast cancer death were observed in 33% and 28% of the patients with ITC-positive cells in PB, as compared to 13% and 6% in the ITC-negative cases, respectively. For the BM analysis, 35% and 25% of the ITC-positive and 12% and 7% of the ITC-negative patients experienced systemic relapse and breast cancer death. Kaplan Meier analyses show that ITC-detection in PB is associated with reduced breast cancer specific survival (p<0.001) and distant disease free survival (p=0.016, log-rank test). Patients with ITC in both PB and BM had an especially poor prognosis. Conclusions: Detection of ITC in larger volumes of PB can be used for selection of patients with an unfavourable clinical outcome and should be considered as a tool for monitoring occult tumor cells. No significant financial relationships to disclose.
Report of toxicities from the multicenter, randomized NNBC 3-Europe trial: 6xFEC versus 3xFEC-3xDoc for high-risk node-negative breast cancer patients.
Authors: C. Thomssen, E. J. Kantelhardt, K. Plueckhahn, C. Veyret, D. Augustin, V. Hanf, D. Paepke, C. Meisner, G. Von Minckwitz, N. Harbeck
Journal: Journal of Clinical Oncology (2010)

554 Background: ASCO guidelines recommend invasion markers uPA/PAI-1 (Harris, JCO 2007) for risk assessment in N0 breast cancer. Also, a St. Gallen-adapted clinicopathologic algorithm (CP) (Schmidt, Ann Oncol 2009) is widely used. Currently, high-risk N0 patients (pts) receive anthracycline-containing adjuvant chemotherapy; the benefit of adding taxanes is not proven. Methods: The prospective NNBC 3-Europe trial compared 3xFEC-3xDoc (FEC-D) versus 6xFE100C (FEC) as adjuvant chemotherapy for high-risk N0 pts. Risk assessment was performed by CP or an uPA/PAI-1 based algorithm (UP). Here we report about side effects during chemotherapy. Results: Between Dec 2002 and Jan 2009, 4,149 pts were recruited. Out of 2,661 high-risk pts (57% UP, 43% CP), 1,334 pts received FEC-D and 1,327 FEC. Pts characteristics are equally distributed. Nonhematologic toxicities are described by NCI-CTC. For grade 3/4 toxicity, in FEC >7,100 cycles were evaluated, and in FEC-D >4,400 (FEC) and >2,900 (D), respectively. For FEC, the only noteworthy toxicity was vomiting (1.0%). For D, grade 3/4 arthralgia was noted in 4.3% of the cycles, infection in 1.6%, mucositis in 1.2%, and neurological side effects in 1.0%. All other severe toxicities were observed in <1.0%. Serious adverse events assessed by the investigators are listed as episodes of hospitalization in the Table. Two pts died during chemotherapy, probably drug related (febrile neutropenia, Doc1; subdural hematoma, Doc1). Four pts died during FEC (3 pts by pulmonary embolism, 1 by cerebral aneurysm hemorrhage). Conclusions: Adjuvant chemotherapy with FEC-D in high-risk N0 breast cancer is feasible. Arthralgia was observed more often in D than in FEC (4.3% vs. <1%). Hospitalization due to neutropenia with fever was seen more often in patients receiving FEC-D. Two of six fatalities during chemotherapy were probably study drug related; one is judged unknown. FEC-D FEC n Mild Moderate Severe n Mild Moderate Severe Hospitalization (episodes) 308 39 119 115 219 24 123 72 Neutropenia + fever 71 6 39 26 40 3 27 10 Neutropenia 38 2 16 20 43 2 16 25 Febrile infections 27 8 15 4 25 6 17 2 Nonfebrile infections 22 3 13 6 17 4 9 4 Anemia 3 1 2 0 4 0 3 1 Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration sanofi-aventis Pfizer, Roche, sanofi-aventis
Peritoneal Carcinomatosis (Pc) from Colo-Rectal Origin. Results of 200 Patients Treated By Radical Surgery (Crs) Plus Hyperthermic Intraperitoneal Chemotherapy (Hipec) at the Catalonian Peritoneal Carcinomatosis Program (Spain)
Authors: P. Barrios, O. Crusellas, J. Castellvi, F. Losa, G. Soler, V. Fuste, M. Martin, G. Galofre, I. Ramos
Journal: Annals of Oncology (2014)
Abstract 13154: Isotropic Calcium Scoring sing 0.5 mm Reconstructions from 320-Detector Row CT Datasets Identifies More Patients with Non-Zero Agatston Score and Hence More Subclinical Atherosclerosis, Compared to Standard 3.0 mm Reconstructions
Authors: Anum Aslam, Alexander J Abramowicz, Ammar Chaudhry, Usman S Khokhar, Michael J Cortegiano, Michael Poon, Szilard Voros
Journal: Circulation (2012)
Modulation of Clinical Expression and Band 3 Deficiency in Hereditary Spherocytosis
Authors: N. Alloisio, P. Texier, A. Vallier, M.L. Ribeiro, L. Morlé, M. Bozon, E. Bursaux, P. Maillet, P. Gonçalves, M.J.A. Tanner, G. Tamagnini, J. Delaunay
Journal: Blood (1997)
Older-age AML: Disease biology and dose response
Authors: T. Buchner, W. E. Berdel, C. Haferlach, T. Haferlach, S. Schnittger, H. L. Serve, M. C. Sauerland, A. Heinecke, B. Wörmann, W. Hiddemann
Journal: Journal of Clinical Oncology (2007)

7058 Background: In 2602 pts entering two sequential trials the 47% pts of 60+y compared to the younger pts achieved 55 vs 71% CR, 19 vs 41% OS and 77 vs 54% RR (relapse risk) at 3 years. While the trials addressed various options for both de-novo and secondary AML understanding the age related biology of AML required restriction to pts comparable in history, therapy and availability of risk factors. Methods: We therefore selected from the two trials pts with de-novo AML and known karyotype assigned to one of two different intensity induction regimens, either TAD-HAM (HAM, high-dose araC 3(age &lt;60) and 1(age 60+) g/m 2 x6), or HAM-HAM. All pts received TAD consolidation and monthly reduced TAD maintenance. Results: In the 1284 selected pts the CR rate is 60% in pts of 60+y and 70% in those of 16 −&lt;60y (p&lt;.001), the OS is 23 vs 41% (log rank p&lt;0.001) and the RR is 73 vs 50% (p&lt;.001). There are advantages for younger pts in favorable (16 vs 7%) and unfavorable (18 vs 24%) karyotypes (p&lt;.001) whereas WBC (p=.002) and LDH (p=.002) are lower in the older pts. Among normal karyotypes (52%) the favorable NPM mutation in absence of Flt3 mutation account for 33% of NPM/Flt3 combinations in older and 37% in younger pts (n.s.). The inferior CR, OS and RR in the older vs younger pts is seen in all prognostic subgroups. Thus, the OS at 3 years is 36 vs 62% in favorable (p=.001), 2 vs 14% in unfavorable karyotypes (p=.001), 25 vs 42% in low WBC (p&lt;.001), 21 vs 38% in high WBC (p&lt;.001), 23 vs 42% in low LDH (p&lt;.001), 16 vs 38% in high LDH (p&lt;.001), 30 vs 43% in low day 16 blasts (p&lt;.001), 19 vs 38% in high day 16 blasts (p&lt;.001) and even 50 vs 63% in pts with NPM+/Flt3- mutation (p=.020). In contrast, outcome does not vary by randomization for TAD-HAM vs HAM-HAM chemotherapy. Conclusions: The lack of dose response and the modest age related differences in defined risk profiles suggest hitherto unknown determinants of the poor outcome in older age AML across all subsets. These experiences may indicate the way toward novel experimental options instead of further escalation. No significant financial relationships to disclose.
NCCN task force report
Authors: Julie R. Gralow, J. Sybil Biermann, Azeez Farooki, Monica N. Fornier, Robert F Gagel, Rashmi Kumar, Georgia Litsas, Rana McKay, Donald A Podoloff, Sandy Srinivas, Catherine H. Van Poznak
Journal: Journal of the National Comprehensive Cancer Network (2007)
Abstract 13589: A Novel Role of Intercellular Adhesion Molecule-1 Signaling via Notch1 in Mediating Bone Morphogenetic Protein-2 Expression in Human Aortic Valve Interstitial Cells
Authors: Dong Wang, Qingchun Zeng, Rui Song, Lihua Ao, Joseph C Cleveland Jr, David A Fullerton, Xianzhong Meng
Journal: Circulation (2012)

Calcific aortic valve stenosis is a chronic inflammatory disease. Aortic valve interstitial cells (AVICs) play an important role in the valvular inflammatory and osteogenic responses. We observed t...
Frosted Branch Angiitis Associated with Cytomegalovirus Retinitis
Authors: Luis Alberto Aguilar Lozano, Alejandra Gonzalez Dibildox
Journal: Ophthalmology (2016)

A 41-year-old man with AIDS presented with decreased vision in the left eye; he denied other symptoms. Medications included efavirenz, tenofovir, and emtricitabine, and his CD4 cell count was 31 cells/μL. He had been diagnosed 8 months previously with acute retinal necrosis in the right eye, with no light perception. Examination of the left eye showed minimal inflammation in the anterior chamber and vitreous. Ophthalmoscopy showed hemorrhagic papillitis, retinal necrosis, hemorrhage, and diffuse vascular sheathing. Induction treatment was started with intravenous ganciclovir and HAART adjustment.
<i>Notes from the Field</i>: Administration Error Involving a Meningococcal Conjugate Vaccine — United States, March 1, 2010–September 22, 2015
Authors: John R. Su, Elaine R. Miller, Jonathan Duffy, Bethany M. Baer, Maria V. Cano
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

Menveo (GlaxoSmithKline, previously Novartis AG) is a conjugate vaccine that was recommended in October 2010 for routine use in adolescents (preferably aged 11 or 12 years, with a booster at 16 years), and among persons aged 2 through 54 years with certain immunosuppressive conditions, to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135 (1). These recommendations have since been updated (2). Menveo is supplied in two vials that must be combined before administration. The MenA lyophilized (freeze-dried) component must be reconstituted with the MenCYW-135 liquid component (Figure). To administer the vaccine, the liquid component is drawn into a syringe, and used to reconstitute the lyophilized component. The resulting solution is administered by intramuscular injection. Failure to prepare Menveo as directed by the manufacturer's instructions can lead to lack of protection against the intended pathogens (N. meningitidis serogroups A, C, Y, and/or W-135) (3). Recently, an immunization provider administered only the lyophilized component of Menveo, subsequently administered a properly prepared dose of Menveo to the same patient, and asked CDC if this practice was safe. This question prompted CDC to search the Vaccine Adverse Event Reporting System (VAERS) database for reports during March 1, 2010-September 22, 2015, of only one component of Menveo being administered. Additionally, to more broadly identify disproportional reporting of adverse events in general following Menveo immunization compared with other vaccines in VAERS (including errors in vaccine preparation and administration), the Food and Drug Administration performed data mining with empiric Bayesian methods (4).
Abstract 17067: Brain Natriuretic Peptide (BNP) Suppresses Neutrophil Superoxide Release: Attenuation in Patients with Congestive Heart Failure (CHF)
Authors: Saifei Liu, Doan T Ngo, Yuliy Y Chirkov, Abdul R Sheikh, Giovanni Licari, Simon Stewart, John D Horowitz
Journal: Circulation (2012)

Background: The release of brain natriuretic peptide (BNP) in patients with congestive heart failure (CHF) has been presumed to serve a homeostatic function. However equivocal clinical benefit asso...
Abstract 17580: Pioglitazone Prevents Intimal Hyperplasia In Experimental Rabbit Vein Graft
Authors: Koichi Morisaki, Rei Shibata, Hiroshi Banno, Masayoshi Kobayashi, Kiyohito Yamamoto, Toyoaki Murohara, Kimihiro Komori
Journal: Circulation (2010)

Background: A recent clinical trial, PROactive, demonstrated that peroxisome proliferators-activated receptor γ ligand, pioglitazone improved cardiovascular outcome in patients with type II diabete...
Action of Air Pollutants and Polycyclic Hydrocarbons on the Respiration of fetal Calf-Kidney Cell Culture 2
Authors: C. Bottex, R. Giordani, P. Deschaux, R. Fontanges
Journal: JNCI Journal of the National Cancer Institute (1973)

The action of atmospheric air pollutants (or their extracts) and some polycyclic synthetic hydrocarbons on the metabolism of fetal calf-kidney cell cultures was investigated at several concentrations as a function of exposure time. At first, the tested agents inhibited respiratory exchanges. However, after a 72-hour treatment of cultured cells with an organic extract or some polycyclic synthetic hydrocarbons, we observed some respiratory hyperactivity.
Abstract O.32: An Improved Point-of-care Differentiation Of Kawasaki Disease From Other Febrile Illnesses
Authors: Shiying Hao, Bo Jin, Zhou Tan, Zhen Li, Jun Ji, Adriana Tremoulet, Jane C Burns, Harvey J Cohen, Xuefeng B Ling
Journal: Circulation (2015)

Background: Kawasaki disease (KD) shares many clinical features with other pediatric febrile illnesses (FC). Clinical confusion can lead to a missed or delayed diagnosis that increases the risk of coronary artery damage. In the present study, we improved our previous KD diagnostic algorithm for point-of-care diagnosis. Methods and Results: We reviewed clinical records of 534 acute KD and 318 FC patients (development dataset) and subsequent 268 acute KD and 161 FC patients (validation dataset). KD subjects met the American Heart Association definition. Using clinical data and lab test results, we integrated our previously developed linear discriminant analysis (LDA)-based clinical model with a newly developed decision tree-based algorithm to improve KD diagnosis. To train the decision trees, sub cohorts were constructed based upon the 5 KD classic criteria. Our 1 st clinical model (LDA) stratified the subjects into FC (FC diagnosis, negative predictive value NPV &gt;=95%), undecided (88/802 KD, 167/479 FC), and KD (KD diagnosis, positive predictive value PPV &gt;=95%) subgroups. The subsequent 2 nd clinical model (decision trees) further classified the undecided group into FC, undecided, and KD subgroups, resulting in a much-improved algorithm with only 59/479 FC (Specificity&gt;76%) and 26/802 KD (Sensitivity&gt;95%) undetermined. Conclusions: Our computer-based algorithm that incorporates only clinical findings and readily available clinical laboratory data now has sufficient sensitivity and specificity in distinguishing acute KD from FC patients that a multicenter, prospective clinical trial is warranted to test the performance of the diagnostic algorithm against the gold standard of expert clinical opinion.
Neoadjuvant chemoradiotherapy in rectal cancer patients (pt) with oxaliplatin (Ox) and capecitabine (Cp): Results of a phase II trial
Authors: J. Gasent Blesa, V. Alberola Candel, O. Juan, M. Provencio Pulla, V. Giner Marco, C. Gravalos, I. Fernandez, C. Llorca
Journal: Journal of Clinical Oncology (2009)

e15101 Background: Between April 2006 and May 2008, 27 rectal adenocarcinoma pt were included (cT3: 25 pt, T4: 2 pt, N0: 11 Pt, N+: 16 pt), stages II-III, RMN staged, 14 male and 13 female. Mehtod: Neoadjuvant treatment was: Ox: 50 mg/m2 weekly, oral Cp: 825 mg/m2 tid the days of the Rt, and a Rt of 50.4 Gy. 9 pt had a lower third tumor, 9 middle, 9 upper. Surgery was planned 6–8 weeks after treatment´s end. 4 adjuvant chemotherapy cycles with Xelox were planned. Results: 7 pt had pCR (26%), 2 pt progression disease 18 pt tumor downstaging(dwst). Percentages of dwst were: T 85%, N 37%. Sphincter preservation (sp) was 81.9%, for tumors of the lower third sp was 44.4%. Presurgical (prsrg) RMN did not predict the pathological result in 21 pt. Main side effects: Dermatitis G1 in 21 pt, and G2 in 4 pt. Diarrhea 12 pt G1, 11 pt G2, and 4 pt G3. Hand and foot G1 5 Pt and G2 4 pt. Paresthesias G1 10 pt, G2 7 pt. Leucopenia 6 pt G1. 4 Pt did not complete treatment because of toxicity. Median Rt dose was 49.7 Gy (47.5–50.4 Gy).At a mean follow up of 22.5 months (7–31) 4 pt presented metastatic disease (15% ), none in the pCR group. Mean pre-neoadjuvant (preneo) CEA was 6.8 ng/ml (2.1–17.0). There was difference statistically significant when compared preneo CEA vs prsrg CEA: 2.72 ng/ml inferior with the second outcome (p&lt;0.001). Mean prsurg CEA was 4.1 (0.1–12.0). In the subgroup with pCR the mean prsrg CEA was 1.1 (0.5–1.5), and in non-pCR it was 5.1 (0.1–12.0). Comparing the prsrg CEA between pCR and the non-pCR subgroups, the mean difference was 4.0 ng/ml greater in the non pCR. This difference was statistically significant (p=0.002, 95% CI: 1.68–6.3).We found a nadir of &lt;5ng/ml as significantly associated with pCR (p=0.036). Conclusions: Preoperative chemoradiotherapy with Ox and Cp, is safe and well tolerated. Offers an interesting ratio of pCR, and of tumor downstaging. Prsrg CEA level and CEA nadir should be studied as predictors of pCR. It is possible that with more patients, the significant nadir level could be lower. We consider this combination and the CEA nadir interesting to be included in further studies. No significant financial relationships to disclose.